{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:03:10Z","timestamp":1782324190656,"version":"3.54.5"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Patients with cervical cancer exhibiting full-thickness (FT) and outer full-thickness (OFT) stromal invasion after radical hysterectomy face high risks of recurrence, yet optimal adjuvant radiotherapy strategies remain debated.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine if simultaneous integrated boost (SIB) radiotherapy increases 3-year progression-free survival (PFS) by 13% vs conventional chemoradiotherapy (CRT) among patients with cervical cancer exhibiting FT or OFT stromal invasion after surgery.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This phase 3, single-center, randomized clinical superiority trial enrolled 466 patients in Shanghai Cancer Center with FIGO (International Federation of Gynecology and Obstetrics) 2018 stage IB to IIA and IIIC cervical cancer and pathologically confirmed FT or OFT stromal invasion from October 15, 2019, to September 20, 2024. Data were analyzed in October 2024.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomized to receive conventional CRT (50.4 Gy in 28 fractions plus cisplatin, 40 mg\/m2<\/jats:sup>\/wk) or CRT plus SIB radiotherapy (58.8 Gy in 28 fractions).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was 3-year PFS. Secondary end points included overall survival (OS), acute and late toxic effects, and progression patterns. All outcomes were analyzed under the intention-to-treat principle.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 466 patients with cervical cancer presenting with FT or OFT stromal invasion after radical hysterectomy were randomized (233 in non-SIB radiotherapy group: median age, 53 years [IQR, 46-59 years]; 233 in SIB radiotherapy group: median age, 55 years [IQR, 48-60 years]). At a median follow-up of 33 months (range, 8-54 months), SIB radiotherapy significantly improved 3-year PFS compared with conventional CRT (84.6% vs 76.8%; P<\/jats:italic>\u2009=\u2009.04), corresponding to a 35.7% reduction in progression risk (hazard ratio [HR], 0.64; 95% CI, 0.42-0.99; P<\/jats:italic>\u2009=\u2009.04). Multivariable analysis identified adenocarcinoma (HR, 2.68; 95% CI, 1.62-4.44; P<\/jats:italic>\u2009&amp;lt;\u2009.001), adenosquamous carcinoma (HR, 2.66; 95% CI, 1.06-6.66; P<\/jats:italic>\u2009=\u2009.04), tumor size of 4 cm or more (HR, 1.81; 95% CI, 1.17-2.81; P<\/jats:italic>\u2009=\u2009.01), lymphovascular space invasion (HR, 2.88; 95% CI, 1.45-5.72; P<\/jats:italic>\u2009=\u2009.003), and positive vaginal margins (HR, 4.60; 95% CI, 1.97-10.73; P<\/jats:italic>\u2009&amp;lt;\u2009.001) as independent risk factors of poorer PFS, while SIB radiotherapy remained protective (HR, 0.59; 95% CI, 0.38-0.91; P<\/jats:italic>\u2009=\u2009.02). Profiles of toxic effects were comparable between groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial of postoperative patients with cervical cancer presenting with FT or OFT stromal invasion, SIB radiotherapy significantly enhanced PFS without increased toxic effects. The clinical benefits and comparable profiles of toxic effects support its integration into adjuvant care.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>Chinese Clinical Trial Registry Identifier: ChiCTR1900027272<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.32501","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:30:35Z","timestamp":1758295835000},"page":"e2532501","source":"Crossref","is-referenced-by-count":2,"title":["Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion"],"prefix":"10.1001","volume":"8","author":[{"given":"Suping","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihao","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"3","key":"zoi250920r1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi250920r2","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi250920r3","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"12","key":"zoi250920r4","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data.","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"issue":"6","key":"zoi250920r5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/1055-9965.EPI-22-0674","article-title":"Trend in cervical cancer incidence and mortality rates in china, 2006-2030: a bayesian age-period-cohort modeling study.","volume":"32","author":"Yuan","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"zoi250920r6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.979809","article-title":"The burden of cervical cancer in China.","volume":"12","author":"Shen","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"zoi250920r7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/gyno.1999.5387","article-title":"A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study.","volume":"73","author":"Sedlis","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"24","key":"zoi250920r8","doi-asserted-by":"publisher","first-page":"7368","DOI":"10.7150\/jca.50752","article-title":"The clinical and prognostic implication of deep stromal invasion in cervical cancer patients undergoing radical hysterectomy.","volume":"11","author":"Zhu","year":"2020","journal-title":"J Cancer"},{"issue":"2","key":"zoi250920r9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2014.08.037","article-title":"Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies.","volume":"135","author":"Boyle","year":"2014","journal-title":"Gynecol Oncol"},{"key":"zoi250920r10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1353813","article-title":"Simultaneous integrated boost on pathologic lymph nodes safely improves clinical outcomes compared to sequential boost in locally advanced cervical cancer: a multicenter retrospective study.","volume":"14","author":"Guigo","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"zoi250920r11","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1093\/oncolo\/oyab013","article-title":"Clinical implication of simultaneous intensity-modulated radiotherapy boost to tumor bed for cervical cancer with full-thickness stromal invasion.","volume":"27","author":"Zhang","year":"2022","journal-title":"Oncologist"},{"key":"zoi250920r13","doi-asserted-by":"publisher","journal-title":"N Engl J Med","DOI":"10.1056\/NEJM199904153401503"},{"issue":"20","key":"zoi250920r14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"zoi250920r15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1392639","article-title":"Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy.","volume":"14","author":"Galicia-Carmona","year":"2024","journal-title":"Front Oncol"},{"issue":"10434","key":"zoi250920r16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"zoi250920r17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi250920r18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/ijgc-2019-000556","article-title":"Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer.","volume":"29","author":"Cao","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"zoi250920r19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1525-1438.1999.09895.x","article-title":"Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?","volume":"9","author":"Lai","year":"1999","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"zoi250920r20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ygyno.2014.08.018","article-title":"Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.","volume":"135","author":"Rose","year":"2014","journal-title":"Gynecol Oncol"},{"key":"zoi250920r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.04.020","author":"Creasman","year":"2009","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"zoi250920r22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijrobp.2005.10.019","article-title":"A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.","volume":"65","author":"Rotman","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"zoi250920r23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ygyno.2021.06.017","article-title":"Beyond Sedlis\u2014a novel histology-specific nomogram for predicting cervical cancer recurrence risk: an NRG\/GOG ancillary analysis.","volume":"162","author":"Levinson","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1","key":"zoi250920r24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","article-title":"Validation of the 2018 FIGO cervical cancer staging system.","volume":"152","author":"Matsuo","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"2","key":"zoi250920r25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ygyno.2007.06.026","article-title":"Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer.","volume":"107","author":"Horn","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"5","key":"zoi250920r26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/0002-9378(80)90285-9","article-title":"Analysis of factors contributing to treatment failures in stages IB and IIA carcinoma of the cervix.","volume":"138","author":"Chung","year":"1980","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"zoi250920r27","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/annonc\/mdg412","article-title":"Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis.","volume":"14","author":"Morice","year":"2003","journal-title":"Ann Oncol"},{"issue":"40","key":"zoi250920r28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017301","article-title":"Prognostic value of lymphovascular space invasion in patients with early stage cervical cancer in Jilin, China: a retrospective study.","volume":"98","author":"Yan","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"zoi250920r29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.5732\/cjc.009.10528","article-title":"Influence of lymph vascular space invasion on prognosis of patients with early-stage cervical squamous cell carcinoma.","volume":"29","author":"Yan","year":"2010","journal-title":"Chin J Cancer"},{"issue":"3","key":"zoi250920r30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00404-017-4597-0","article-title":"Risk of parametrial invasion in women with early stage cervical cancer: a meta-analysis.","volume":"297","author":"Ma","year":"2018","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"zoi250920r31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ijrobp.2018.05.076","article-title":"Survival benefit of adjuvant brachytherapy after hysterectomy with positive surgical margins in cervical cancer.","volume":"102","author":"Li","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"zoi250920r32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12094-023-03283-6","article-title":"The impact of boost radiation therapy after hysterectomy on cervical cancer patients with close or positive resection margins.","volume":"26","author":"Lee","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"zoi250920r33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000485840","article-title":"Predictive factors of pelvic lymph node metastasis in early-stage cervical cancer.","volume":"41","author":"Nanthamongkolkul","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"3","key":"zoi250920r34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ygyno.2016.10.022","article-title":"Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? a population based study.","volume":"143","author":"Mahmoud","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"29","key":"zoi250920r35","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1200\/JCO.22.02769","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.","volume":"41","author":"Peters","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250920r36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3802\/jgo.2015.26.1.3","article-title":"Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors.","volume":"26","author":"Matsuo","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"zoi250920r12","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Cancer Institute. November 27, 2017. Accessed August 11, 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839090\/liu_2025_oi_250920_1757687824.44211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:30:37Z","timestamp":1758295837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839090"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.32501","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}